This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Health groups raise concerns over patents for rare disease drugs

Health groups and patient advocates are raising concerns over patent monopolies on rare disease drugs in India. They argue that these monopolies, like the one held by Roche for the spinal muscular atrophy drug Risdiplam, restrict access to affordable medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i1HIR4y
via IFTTT

Venus Remedies gets GMP approval for pre-filled syringe facility

Indian pharmaceutical company Venus Remedies received a significant approval from the Malaysian authorities. The company's Baddi facility, equipped with advanced robotic technology, met the stringent quality standards for producing pre-filled syringes. This recognition paves the way for Venus Remedies to expand its global presence and provide critical medications to more countries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mJBNakw
via IFTTT

CDSCO may regulate health supplements to stem unapproved claims by firms

A government panel in India is proposing stricter regulations on health claims made by supplement manufacturers. The panel suggests shifting control from the food safety authority to the drug regulator, aiming to curb exaggerated claims related to disease treatment or risk reduction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ichOSme
via IFTTT

US firm Alkomex to expand R&D footprint in India

Global pharmaceutical company Alkomex GBN is expanding its research and development operations into India. The company has appointed nutraceuticals expert Dr. Sanjay Agrawal as Scientific Advisor to lead these efforts. Based in Ahmedabad, Dr. Agrawal will oversee research and strategic initiatives, integrating Indian research into Alkomex's global operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O0euwlI
via IFTTT

FSSAI sets stricter rule for antibiotics in food items

"If enforced strictly, the regulations will ensure safer food products for consumers by setting stricter residue and contaminant limits across a variety of food items and help in dealing with antimicrobial resistance," said George Cheriyan, working president of Consumers Protection Association (CPA). The FSSAI has also prohibited the use of antibiotics during honey production and reset the limit of the chemicals ochratoxin A and deoxynivalenol in wheat, wheat bran, barley, rye and coffee.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z6CwgT3
via IFTTT

Bajra roti or wheat roti? Which is better for health and weight loss?

Choosing bajra roti over wheat can be a great step toward better health and well-being. Here are the key benefits of choosing bajra roti over wheat for a healthier lifestyle.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H0mS6M3
via IFTTT

Dr Reddy's recalls over 3.3 lakh bottles of generic medication in US: USFDA

Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing issues. The recall is due to the presence of an impurity above FDA limits. The recall affects 30 mg, 60 mg, and 90 mg strengths, with the affected lot produced in India. The recall was initiated on October 9, 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DIbUnKx
via IFTTT

Apollo Hospitals announces Rs 1,625 crore expansion in Mumbai and Lucknow

Apollo Hospitals announces a major expansion plan in Mumbai and Lucknow with a total investment of Rs 1625 crore over the next four years. The expansion, involving a 500-bed facility in Worli and a 200-bed extension in Lucknow, will be funded through internal accruals and debt financing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gVjTe08
via IFTTT

From fish to seeds: 5 excellent sources of Omega-3 fats for a healthier diet

Omega-3 fatty acids are essential fats that play a crucial role in maintaining heart health, supporting brain function, and reducing inflammation. While fatty fish are well-known sources, there are several other foods you can include in your diet to ensure you’re getting enough omega-3s. Here are five excellent sources to consider:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7aJrhny
via IFTTT

Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29

Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and inorganic growth. The merger has received NSE and BSE approvals, with a shareholders meeting scheduled for November 28, 2024. The combined entity will focus on pharma CDMO, specialty chemicals CDMO, and APIs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ITczxfL
via IFTTT